Pfizer berobenatide: VESPER-3 monthly GLP-1
Decision brief
Answer first · skim in under a minute
Pfizer's monthly GLP-1 RA berobenatide (acquired from Metsera) shows continued weight loss in VESPER-3 Phase 2b data. This analysis covers efficacy, safety, and strategic implications for pharma teams.
Pfizer’s Phase 2b VESPER-3 study of berobenatide (PF’3944 / MET-097i), an ultra-long-acting injectable GLP-1 receptor agonist, showed continued weight loss after switching from weekly titration to monthly maintenance dosing. Topline results report up to 12.3% mean placebo-adjusted weight loss at week 28 in adults with obesity or overweight without type 2 diabetes.
Contents9 sections
Key Takeaways
- Primary endpoint met: week-28 weight reduction superior to placebo in all four dose regimens (P < 0.001).
- Peak placebo-adjusted loss reported: 12.3% at week 28 (efficacy estimand); Arm 1 about 10%.
- Design: up to two titration steps, weekly dosing to week 12, then monthly dosing to week 28 (study continues to week 64).
- Pfizer plans Phase 3 monthly regimens including a higher 9.6 mg maintenance dose and says 10 Phase 3 trials with PF’3944 are expected to advance in 2026.
What did Pfizer announce from VESPER-3?
Pfizer said VESPER-3 tested whether PF’3944 could keep losing weight after a four-fold drop in dosing frequency from weekly to monthly injections, while remaining tolerable. Detailed results were slated for presentation on 6 June 2026 at the American Diabetes Association’s 86th Scientific Sessions.
Primary disclosure: Pfizer press release on VESPER-3 monthly dosing and the companion wire on Business Wire.
Which efficacy numbers define the competitive claim?
At week 28, Arms 1 and 3—the low and medium monthly maintenance regimens Pfizer plans for Phase 3—achieved about 10% and 12.3% placebo-adjusted weight loss. The company said weight loss continued after the weekly-to-monthly switch with no plateau at week 28, supporting expectations of further loss through week 64.
- Population: obesity or overweight without type 2 diabetes
- Molecule codes: PF’3944 / MET-097i (berobenatide)
- Week-28 max placebo-adjusted loss: 12.3%
- Statistical bar: P < 0.001 vs placebo across four arms
- Planned higher Phase 3 monthly dose: 9.6 mg
How do later ADA presentations expand the Phase 2b picture?
A subsequent Pfizer release on ADA data described berobenatide across VESPER-1, VESPER-2, and VESPER-3, including VESPER-2 weekly dosing in obesity with type 2 diabetes and a 2.2% HbA1c reduction at 1.6 mg weekly (on-treatment estimand) versus 0.2% on placebo at week 28.
See Pfizer’s ADA Phase 2b berobenatide update.
What remains unproven for BD and competitive outlook?
Week-28 Phase 2b results do not establish Phase 3 success, cardiovascular outcomes, manufacturing scale, or payer positioning versus weekly incretin market leaders. Competitor efficacy cross-trial comparisons are not validated here. Stock-price reactions reported by secondary outlets are omitted.
Implications for obesity pipeline diligence
Monthly maintenance after weekly titration is the strategic differentiator Pfizer is underwriting into a large 2026 Phase 3 program. Diligence should track which monthly doses enter Phase 3 protocols, GI tolerability discontinuations, and whether week-64 VESPER-3 confirms continued slope without new safety signals.
Registry monitoring for related obesity studies can start at ClinicalTrials.gov.
Related NovaPharma coverage
- J&J ASCO 2026 data and oncology catalysts
- Biopharma news week of June 2026
- FDA gene therapy guidance for BD teams
Frequently Asked Questions
What did VESPER-3 show for monthly berobenatide?
Pfizer reported Phase 2b VESPER-3 topline results with up to 12.3% mean placebo-adjusted weight loss at week 28 (efficacy estimand). Weekly titration through week 12 was followed by monthly dosing to week 28; all four regimens beat placebo (P < 0.001).
Which doses is Pfizer taking into Phase 3?
Arms 1 and 3 delivered about 10% and 12.3% placebo-adjusted weight loss at week 28 and are described as the low and medium monthly maintenance regimens planned for Phase 3, with Pfizer also planning a higher 9.6 mg monthly maintenance dose.
What is still unknown after VESPER-3?
VESPER-3 continues to week 64; week-28 data show no plateau yet but do not prove long-term durability, cardiovascular outcomes, or commercial share versus weekly GLP-1 competitors.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for berobenatide.
Unlock full calendar →Pfizer pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…